ERBB2 and breast cancer: The immunohistochemical (IHC) reports of the enrolled BC patients were used to determine the receptor status (oestrogen, progesterone, and human epidermal growth factor receptor 2), cellular differentiation status (grade) and proliferation index (Ki67) of the tumour lesions.